 |
 |
 |
 |
 |
 |
 |
 |
HIV Drug Pricing & Pharmaceutical Company News
Drug Pricing: Overview
- The Price Isn't Right (January 25, 2008)
BMS raises HIV/AIDS drug prices, refuses to engage with treatment activists.
In Housing Works AIDS Issues Update, from Housing Works - An Overview of AIDS Drug Access in the United States (May 2004)
Transcript of a talk by Christine Lubinski, Executive Director of the HIV Medicine Association.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Defining the Impact of AIDS Drug Pricing on the Private Sector (May 2004)
Transcript and slides of a talk by Michael Allerton, HIV Operations Policy Coordinator at the Permanente Medical Group.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Defining the Impact of AIDS Drug Pricing on the Public Sector (May 2004)
Transcript and slides of a talk by Lanny Cross, Program Manager of the New York State AIDS Drug Assistance Program.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Untangling the Economics of Drug Pricing (May 2004)
Transcript and slides of a talk by Joshua P. Cohen, a senior research fellow at the Tufts Center for the Study of Drug Development.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Glaxo Will Further Cut Prices of AIDS Drugs to Poor Nations (April 28, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Gilead Offers Tenofovir to Developing Countries at Cost (April 4, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Patient Care Squeezed by Soaring Drug Prices (April 2002)
An in-depth examination of the drug-pricing war raging in the United States.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Drug Pricing: News & Analysis
- Boehringer, Gilead Freeze Antiretroviral Prices for Some U.S. Agencies (June 5, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Student Global AIDS Campaign Responds to Abbott's Decision to Reduce Price of Kaletra in Low and Middle Income Countries (April 10, 2007)
From Student Global AIDS Campaign - Optimal Treatment for 40,000 New HIV Cases in U.S. Will Cost $12 Billion Annually, Study Says (November 2, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Free Trade, Expensive Drugs (Fall 2006)
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America - AIDS Activists Cry Foul as Drug Companies Push Prices to Record Levels (July 9, 2005)
To read PDF, click here
From AIDS Treatment Activists Coalition - Medical Innovation Prize Fund: New Idea in Drug Development (June 20, 2005)
A U.S. congressman's plan would allow generic versions of a drug to be sold right after approval.
In AIDS Treatment News, from AIDS Treatment News - Hundreds of U.S. AIDS Groups Demand Freeze on AIDS Drug Prices (October 15, 2004)
Two hundred AIDS organizations sign the letter, which is directed at seven major drug companies.
From AIDS Treatment Activists Coalition - How to Ease the Crisis in Drug Pricing (July 2004)
An analysis of several possible solutions to the trend of escalating drug prices in the United States.
To read PDF, click here
In Project Inform Perspective, from Project Inform - Prominent Medical Group Calls for Full Disclosure on Drug Studies (June 16, 2004)
The American Medical Association proposes a national registry to prevent U.S. pharmaceutical companies from hiding negative clinical trial results.
In Boston Globe - A Physician's Call to Action: Clinicians Must Act Against Drug Pricing Increases (May 2004)
Transcript and slides of a talk by Benjamin Young, M.D., a clinical instructor at the University of Colorado Health Sciences Center.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Summary of Highlights From IAPAC Pharmacoeconomics Summit (May 2004)
The one-day summit, held on April 6, 2004, was entitled "Examining the Pharmacoeconomics of U.S. AIDS Drug Access".
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Critics Decry Escalating HIV/AIDS Drug Prices (January 16, 2004)
In The Washington Blade
The Ritonavir (Norvir) Price Increase
- GSK Joins Lawsuit Against Abbott Over Price of Ritonavir (November 12, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Pharmacies, Drug Wholesaler File Lawsuit Against Abbott Over Ritonavir Price (October 30, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Wall Street Journal Examines Reason Abbott Increased Price of Antiretroviral Norvir (January 3, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Aetna Files Lawsuit Against Abbott Over 400% Price Increase of Ritonavir (May 27, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - U.S. Government Holds Hearing on Generic Production of Ritonavir (May 26, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Abbott's Norvir Price Hike Is Bad Medicine (May/June 2004)
Bob Huff explains why the December 2003 ritonavir price increase may well doom the development of boosted protease inhibitors.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Two HIV-Infected Patients File U.S. Antitrust Suit Against Ritonavir Price Hike (April 20, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Hearing on Drug Reimportation to Include Discussion of Abbott's Pricing of Antiretroviral Norvir (April 14, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Opinion/Views
- Tangle of Interests and Disclosure Omissions Cracks Authors' Case for Early, Aggressive Treatment (January 2005)
AIDS advocate Mike Barr expresses concern over the influence of drug company money on HIV clinical practice -- and over some journals' lax disclosure policies.
In TAGline, from Treatment Action Group - "On the Take" Explores Money, Medicine and Corruption (October 10, 2004)
Former New England Journal of Medicine editor Jerome P. Kassirer's new book deeply criticizes the influence of pharmaceutical industry money on medicine.
In The Boston Globe - Veteran NEJM Editor Takes on Big Pharma as No One Before; Calls for Sweeping Reforms (September 2004)
Dr. Marcia Angell's new book blisteringly critiques the pharmaceutical industry.
In TAGline, from Treatment Action Group - Allow Imported HIV/AIDS Drugs (April 23, 2004)
An op-ed article by Mubarak Dahir, editor of the Express Gay News in Fort Lauderdale, Fla.
In Washington Blade
  |
  |